SuppreMol GmbH

Swiss venture capital firm BioMedPartners has launched its third healthcare investment fund with CHF75m ($75.1m) to pour into a dozen or more European firms – and the VC has its eye on emerging busine

IN VITRO DIAGNOSTICS Mergers & Acquisitions HalioDx Qiagen NV Qiagen Marseille SA Management of Qiagen NV division Qiagen Marseille SA have formed a new company, HalioDx , through a buy-out

“The Pink Sheet” regularly covers significant deal-making in the biopharmaceutical industry. Here is a summary of the most noteworthy transactions occurring between Feb. 28 and March 12. Endo/Salix

Baxter's Bioscience Business has acquired SuppreMol for €200m in what the privately-held German firm's CEO called "a good day for both companies." SuppreMol is developing treatments for autoimmune and